Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTNK-tPA versus urokinase for catheter-directed thrombolysis in acute proximal lower-extremity deep vein thrombosis
ChiCTR2300076938Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2023
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in deep vein thrombosis (DVT) comparing rhTNK-tPA thrombolytic therapy group with Urokinase thrombolytic therapy group (2 arms). Primary endpoints: Proportion of patients with Grade III thrombolysis and Self-report leg pain score. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
tenecteplaseurokinase
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on ChiCTR2300076938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076938.